A novel approach to treating a wide range of diseases, from rare metabolic conditions to cancer, has just secured $4.3M in seed funding. Scarlet Therapeutics Ltd, a biotech firm developing unique red blood cell-based therapeutics, announced the close of its latest round.
The capital infusion, backed by investors including Eos Advisory, SCVC, Oshen Bio, and Daft Capital, will support Scarlet's platform that generates therapeutic red blood cells (tRBCs). These tRBCs are designed to deliver active proteins throughout the body, offering a long life and shielding therapeutics from the immune system, initially targeting hyperammonemia and hyperoxaluria.
